Synergy pharmaceuticals, inc. (SGYP)
Income statement / Quarterly
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Net sales

11,105

-

-

-

5,008

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net sales

-

12,254

8,586

9,400

-

2,314

98

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

3,922

3,885

3,704

3,820

1,722

1,643

1,636

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross profit

7,183

8,369

4,882

5,580

3,286

671

-1,538

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs and expenses:
Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Research and development

2,904

2,844

3,392

1,990

5,876

22,069

18,401

16,406

24,065

25,906

20,679

19,881

20,424

19,525

18,198

24,550

20,946

24,479

13,299

16,449

10,782

9,055

14,344

9,085

7,245

7,626

5,338

5,703

3,883

2,355

1,478

2,295

4,395

Selling, general and administrative

33,887

34,615

40,145

41,779

45,110

52,185

42,788

25,992

14,417

10,954

6,871

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

36,791

37,459

43,537

-

50,986

74,254

61,189

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchased in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

-

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,041

2,506

2,279

3,178

2,908

2,692

2,803

3,278

2,447

1,843

1,919

1,732

2,222

1,103

1,524

1,897

1,220

1,419

Loss from operations

-29,608

-29,090

-38,655

-38,189

-47,700

-73,583

-62,727

-42,398

-38,482

-36,860

-27,550

-26,947

-23,152

-26,919

-22,804

-27,591

-23,452

-26,758

-16,477

-19,357

-13,474

-11,858

-17,622

-11,532

-10,088

-9,545

-7,070

-7,925

-4,986

-3,879

-3,375

-3,515

-5,814

Other Income (Expense)
Interest expense, net

3,369

3,205

3,123

-2,909

1,226

345

790

3,007

1,674

1,673

7,036

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-0

12

-

-

Interest and investment expense, net

-

-

-

-

-

-

-

-

-

-

-

-3,469

-4,291

-5,207

-4,317

-2,511

19

-1

29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt conversion expense

0

0

0

0

0

0

1,209

14,543

0

0

25,615

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

State R&D tax credits

0

0

30

0

0

0

0

126

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tax credits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

83

-

-

-

-

-

250

-

256

-

362

-

-

-

-

-

Interest and investment income/ (expense), net (includes interest expense of $3,750 on Senior Convertible Debentures for the three months ended March 31, 2015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

68

63

48

39

26

20

20

24

23

27

Change in fair value of derivative financial instruments-warrants

-433

2,604

5,644

4,124

55

39

122

-45

-87

-23

260

-30

1,446

-1,542

-268

-42

425

756

223

-484

-77

1,803

-1,093

-764

140

-1,317

8

1,911

4,383

-698

-339

110

-

Total other expense

-3,802

-601

2,551

1,215

-1,171

-306

-1,877

-17,469

-1,761

-1,696

-32,391

-3,499

-2,845

-6,749

-4,585

-2,964

444

838

252

-494

-63

1,819

-1,076

-446

203

-1,013

47

2,299

4,403

-678

-327

134

-

Loss before taxes

-33,410

-

-

-

-48,871

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tax expense

1,133

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from Continuing Operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,381

-

Loss from Continuing Operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,786

Net loss

-34,543

-29,691

-36,104

-36,974

-48,871

-73,889

-64,604

-59,867

-40,243

-38,556

-59,941

-30,446

-25,997

-33,668

-27,389

-30,555

-23,008

-25,920

-16,225

-19,851

-13,537

-10,039

-18,698

-11,978

-9,885

-10,558

-7,023

-5,626

-583

-4,557

-3,702

-3,381

-

Weighted Average Common Shares Outstanding
Basic and Diluted (in shares)

247,994

246,990

246,664

235,924

224,954

224,948

215,484

190,093

179,786

168,127

117,626

113,678

111,328

100,343

96,683

96,190

94,738

94,069

92,056

90,182

90,182

87,482

72,789

66,194

65,806

60,416

54,298

48,657

47,308

46,642

46,167

-

-

Net Loss per Common Share, Basic and Diluted
Net Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,786

Weighted Average Common Shares Outstanding Basic (restated for stock split) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

90,102

88,462

Weighted Average Common Shares Outstanding Diluted (restated for stock split) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

90,102

88,462

Net Loss per Common Share, Basic and Diluted (in dollars per share)

-0.14

-0.12

-0.15

-0.16

-0.22

-0.33

-0.30

-0.31

-0.22

-0.23

-0.51

-0.27

-0.23

-0.34

-0.28

-0.32

-0.24

-0.28

0.18

-0.22

-0.15

-0.11

-0.26

-0.18

-0.15

-0.17

-0.13

-0.12

-0.01

-0.10

-0.08

-0.04

-0.07